MD3522880T2 - Metode de tratare a leziunilor renale acute - Google Patents
Metode de tratare a leziunilor renale acute Download PDFInfo
- Publication number
- MD3522880T2 MD3522880T2 MDE20190903T MDE20190903T MD3522880T2 MD 3522880 T2 MD3522880 T2 MD 3522880T2 MD E20190903 T MDE20190903 T MD E20190903T MD E20190903 T MDE20190903 T MD E20190903T MD 3522880 T2 MD3522880 T2 MD 3522880T2
- Authority
- MD
- Moldova
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- patient
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3522880T2 true MD3522880T2 (ro) | 2021-03-31 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20190903T MD3522880T2 (ro) | 2016-10-05 | 2017-10-05 | Metode de tratare a leziunilor renale acute |
Country Status (33)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2949852T3 (es) | 2015-10-07 | 2023-10-03 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
| BR112018069930B1 (pt) * | 2016-04-13 | 2024-02-20 | Mitobridge, Inc | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica |
| MA46460A (fr) * | 2016-10-05 | 2021-03-17 | Mitobridge Inc | Formes cristallines et salines de composés agonistes de ppar |
| KR20220042150A (ko) * | 2019-07-19 | 2022-04-04 | 비포르 (인터내셔날) 아게 | 신장 손상의 예방 및 치료에의 용도를 위한 페로포틴 억제제 |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| KR20240019753A (ko) * | 2021-03-08 | 2024-02-14 | 아비오닉스 파마 에스에이 | 간 질환을 치료하는 데 유용한 화합물 |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA009119B1 (ru) * | 2003-09-19 | 2007-10-26 | Янссен Фармацевтика Н. В. | 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги |
| AU2005247473A1 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| CN102209532B (zh) * | 2008-10-17 | 2015-07-22 | 西玛贝治疗公司 | 减少小而致密的ldl颗粒的方法 |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| CN105324395A (zh) * | 2013-03-08 | 2016-02-10 | 艾伯维公司 | 治疗急性肾损伤的方法 |
| AU2014247953A1 (en) * | 2013-04-05 | 2015-11-12 | Mitobridge, Inc. | PPAR agonists |
| EP2862574A1 (en) * | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| US10300108B2 (en) * | 2013-12-03 | 2019-05-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| ES2949852T3 (es) * | 2015-10-07 | 2023-10-03 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
-
2017
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Ceased
- 2017-10-05 MX MX2019003949A patent/MX387518B/es unknown
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en active Active
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en not_active Ceased
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh active
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 BR BR112019005539A patent/BR112019005539A2/pt not_active Application Discontinuation
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/it unknown
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3522880T2 (ro) | Metode de tratare a leziunilor renale acute | |
| JP6938705B2 (ja) | 多発性嚢胞腎の予防及び／又は治療薬 | |
| TW201249432A (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| CN114085235B (zh) | 杂环衍生物化合物的制备方法、包含所述化合物的组合物及所述化合物的水合物 | |
| HUT76542A (en) | Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy | |
| IL298833A (en) | Methods for treating or preventing chronic kidney disease | |
| AU2011252151A1 (en) | Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof | |
| HK40008682B (en) | Methods of treating acute kidney injury | |
| HK40008682A (en) | Methods of treating acute kidney injury | |
| CZ182895A3 (en) | Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide per se and for treating diseases, and pharmaceutical composition based thereon | |
| JP6861726B2 (ja) | 糖尿病性腎症の治療薬または予防薬 | |
| US20090281083A1 (en) | Combination Product | |
| WO2023225300A2 (en) | Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto | |
| US9242938B2 (en) | Glycine reuptake inhibitor and use thereof | |
| JPH05950A (ja) | 利尿剤 | |
| JP2000086508A (ja) | ヒスタミン遊離抑制剤 | |
| JPS634807B2 (enExample) | ||
| HK1179890A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction |